Acorn Creek Capital LLC Sells 43 Shares of Eli Lilly and Company $LLY

Acorn Creek Capital LLC trimmed its position in Eli Lilly and Company (NYSE:LLY) by 4.8% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 849 shares of the company’s stock after selling 43 shares during the quarter. Eli Lilly and Company comprises about 0.3% of Acorn Creek Capital LLC’s investment portfolio, making the stock its 26th biggest position. Acorn Creek Capital LLC’s holdings in Eli Lilly and Company were worth $662,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in the company. Mitchell Sinkler & Starr PA increased its holdings in shares of Eli Lilly and Company by 1.2% in the second quarter. Mitchell Sinkler & Starr PA now owns 2,431 shares of the company’s stock worth $1,895,000 after purchasing an additional 30 shares during the last quarter. Valley Brook Capital Group Inc. increased its holdings in shares of Eli Lilly and Company by 1.3% in the second quarter. Valley Brook Capital Group Inc. now owns 1,602 shares of the company’s stock worth $1,249,000 after purchasing an additional 20 shares during the last quarter. Orca Investment Management LLC bought a new stake in shares of Eli Lilly and Company in the second quarter worth about $1,448,000. Ackerman Capital Advisors LLC increased its holdings in shares of Eli Lilly and Company by 5.8% in the second quarter. Ackerman Capital Advisors LLC now owns 272 shares of the company’s stock worth $212,000 after purchasing an additional 15 shares during the last quarter. Finally, Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. bought a new stake in shares of Eli Lilly and Company in the second quarter worth about $40,217,000. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company Stock Down 2.6%

Shares of NYSE:LLY opened at $833.08 on Monday. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $937.00. The business has a 50 day simple moving average of $742.42 and a two-hundred day simple moving average of $765.55. The firm has a market capitalization of $788.47 billion, a PE ratio of 54.45, a price-to-earnings-growth ratio of 1.18 and a beta of 0.47. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.59 by $0.72. The business had revenue of $15.56 billion during the quarter, compared to analyst estimates of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The company’s revenue for the quarter was up 37.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $3.92 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, equities analysts predict that Eli Lilly and Company will post 23.48 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the company. Berenberg Bank reissued a “hold” rating and set a $830.00 price objective (down from $970.00) on shares of Eli Lilly and Company in a research note on Wednesday, September 17th. Deutsche Bank Aktiengesellschaft reduced their price objective on Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating on the stock in a research note on Monday, August 11th. Hsbc Global Res raised Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a research note on Wednesday, August 27th. Weiss Ratings reissued a “hold (c+)” rating on shares of Eli Lilly and Company in a research note on Wednesday, October 8th. Finally, The Goldman Sachs Group boosted their price objective on Eli Lilly and Company from $876.00 to $879.00 and gave the stock a “buy” rating in a research note on Friday. One investment analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and ten have issued a Hold rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $948.06.

Insider Transactions at Eli Lilly and Company

In other news, Director Gabrielle Sulzberger purchased 117 shares of the stock in a transaction that occurred on Tuesday, August 12th. The stock was purchased at an average price of $641.18 per share, for a total transaction of $75,018.06. Following the completion of the acquisition, the director owned 2,703 shares of the company’s stock, valued at approximately $1,733,109.54. This trade represents a 4.52% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO David A. Ricks purchased 1,632 shares of the stock in a transaction that occurred on Tuesday, August 12th. The stock was purchased at an average price of $644.77 per share, with a total value of $1,052,264.64. Following the acquisition, the chief executive officer directly owned 546,601 shares of the company’s stock, valued at $352,431,926.77. This trade represents a 0.30% increase in their position. The disclosure for this purchase can be found here. Insiders have bought 4,514 shares of company stock valued at $2,894,841 in the last ninety days. Corporate insiders own 0.14% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.